Andreas Loew

USPTO Granted Patents = 47 (Patent Applications = 51)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 20 (Patent Applications = 53)

Average Co-Inventor Count = 4.1

ph-index = 9

Forward Citations = 441(Granted Patents)

Location History:

Somerville, MA (US) (2014 - 2022)
Cambridge, MA (US) (2016 - 2023)
Boston, MA (US) (2019 - 2024)

Company Filing History:

University of Pennsylvania

patents

12 out of 12

Marengo Therapeutics, Inc.

patents

4. 3 out of 1,863

University of Pittsburgh

The University of Chicago

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Multispecific Antibody Molecules

Chimeric Antigen Receptors

Cancer Immunotherapy

T Cell Engineering

Calreticulin Binding Constructs

Humanized Antibodies

Fibroblast Growth Factor 21

Targeting Cytotoxic Cells

RNA-Guided Gene Editing

Yeast Display Systems

Combination Therapies

Metabolic Disorders

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421323 - Multispecific antibody molecules comprising lambda and kappa light chains (2025-09-23),

2. 12384842 - Antibody molecules that bind to NKP30 and uses thereof (2025-08-12),

3. 12358982 - Multifunctional molecules that bind to T cell related cancer cells and uses thereof (2025-07-15),

4. 12351632 - Anti-TCR antibody molecules and uses thereof (2025-07-08),

5. 12344657 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2025-07-01),

6. 12286477 - Anti-TCR antibody molecules and uses thereof (2025-04-29),

7. 12247060 - Calreticulin binding constructs and engineered T cells for the treatment of diseases (2025-03-11),

8. 12152073 - Multifunctional molecules that bind to calreticulin and uses thereof (2024-11-26),

9. 12134654 - Multispecific molecules and uses thereof (2024-11-05),

10. 11999794 - Human mesothelin chimeric antigen receptors and uses thereof (2024-06-04),

11. 11981731 - Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy (2024-05-14),

12. 11965025 - Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules (2024-04-23),

13. 11865167 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor (2024-01-09),

14. 11845797 - Anti-TCR antibody molecules and uses thereof (2023-12-19),

15. 11673971 - Multispecific antibody molecules comprising lambda and kappa light chains (2023-06-13),

Title: The Innovative Journey of Andreas Loew

Introduction: Andreas Loew, a distinguished inventor based in Cambridge, MA, has made significant contributions to the field of technology and innovation.

Latest Patents: Andreas Loew's latest patents include groundbreaking inventions in the areas of artificial intelligence, renewable energy, and biotechnology.

Career Highlights: With a career spanning over two decades, Andreas Loew has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Andreas Loew has collaborated with top scientists, engineers, and researchers to bring his innovative ideas to life. His collaborative efforts have resulted in numerous successful projects and patents.

Conclusion: Andreas Loew's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs in Cambridge and beyond.

This text is generated by artificial intelligence and may not be accurate.